Compare Heron Therapeutics Inc (HRTX) vs iShares Core S&P 500 ETF (IVV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs iShares Core S&P 500 ETF — how do they compare? Heron Therapeutics Inc trades at $0.48 (market cap $91.46M), while iShares Core S&P 500 ETF trades at $750.54. The key difference: iShares Core S&P 500 ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| HRTX | IVV | |
|---|---|---|
Market Cap | $91.46M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $1.96 | $763.10 |
52-Week Low | $0.39 | $624.65 |
Enterprise Value | $189.36M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
IVV, tracking the S&P 500, trades at $745.67, down 0.14% with a bearish technical signal from moving averages. The fund remains heavily weighted toward technology stocks, with recent news highlighting concentration risks and debates over valuation. A dividend of $2.00 is scheduled for June 2026, providing income amid market volatility.
Outlook is cautious due to technical weakness and high tech exposure, though long-term growth prospects from AI and earnings strength offer potential. Key risks include market concentration, valuation concerns, and macroeconomic shifts impacting broad index performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About iShares Core S&P 500 ETF
IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.
Read more on IVV →
